Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BridgeBio Pharma, Inc. entered into Equity Distribution Agreement with Goldman Sachs & Co. LLC and SVB Securities LLC valued at up to $450,000,000 (effective 2023-05-04).
- Action
- entry
- Agreement
- atm program
- Counterparty
- Goldman Sachs & Co. LLC and SVB Securities LLC
- Value
- up to $450,000,000
- Effective
- 2023-05-04
Exact text from the filing
On May 4, 2023, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Goldman Sachs & Co. LLC and SVB Securities LLC (the “Sales Agents”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at its sole discretion and pursuant to a prospectus supplement, shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $450,000,000 (the “Placement Shares”), through the Sales Agents.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BridgeBio Pharma, Inc. terminated Open Market Sales Agreement with Jefferies LLC and SVB Securities LLC (effective 2023-05-03).
- Action
- termination
- Agreement
- atm program
- Counterparty
- Jefferies LLC and SVB Securities LLC
- Effective
- 2023-05-03
Exact text from the filing
On May 3, 2023, Jefferies LLC (“Jefferies”) and SVB Securities LLC (formerly known as SVB Leerink LLC, “SVB Securities”), acknowledged and accepted the Company’s prior written notice to terminate the Open Market Sales Agreement SM , dated July 7, 2020, by and among the Company, Jefferies and SVB Securities, for convenience, effective as of May 3, 2023.
View on SEC.gov